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Abstract
The molecular pathogenesis of myelodysplastic syndrome (MDS) and its progression to secondary acute myeloid
leukemia (sAML) remain to be explored. Somatic C-CBL mutations were recently described in MDS. Our study
aimed to determine the role of C-CBL mutations in the progression of MDS to sAML and sought to correlate with
clinicohematological features and outcome. Bone marrow samples from 51 patients with high-risk MDS (13 with
refractory cytopenia with multilineage dysplasia, 19 with refractory anemia with excess blast 1, and 19 with refractory
anemia with excess blast 2) were analyzed for C-CBLmutations at both diagnosis and sAML in the same individuals.
Mutational analysis was performed for exons 7 to 9 of C-CBL gene. Of the 51 paired samples, C-CBLmutations were
identified in 6 patients at the sAML phase. One patient retained the identical C-CBL mutation (G415S) at sAML
evolution and exhibited clonal expansion. The other five patients acquired C-CBL mutations (Y371S, F418S,
L370_Y371 ins L, L399V, and C416W) during sAML evolution. Three of the six patients harboring C-CBL mutations
at sAML had additional genemutations including JAK2V617F, PTPN11, or N-RAS. There was no significant difference in
clinicohematological features and overall survival with respect to C-CBLmutation status. Our results show that C-CBL
mutation is very rare (0.6%) in MDS, but acquisition and/or expansion of C-CBL mutant clones occur in 11.8% of
patients during sAML transformation. The findings suggest that C-CBLmutations play a role at least in part in a subset
of MDS patients during sAML transformation.
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Introduction
Myelodysplastic syndromes (MDSs) are hematological malignancies
characterized by ineffective hematopoiesis and a high-risk transfor-
mation to secondary acute myeloid leukemia (sAML) [1]. MDSs are
clonal hemopathies associated with acquired genetic aberrations. We
and others have shown that genetic or epigenetic abnormalities might
arise during MDS evolution or its progression to sAML [2,3]. Efforts
have been made to determine the molecular pathogenesis of the pro-
gression of MDS to sAML as well as their clinical impact.
Human C-CBL gene locates on chromosome 11q23.3 and encodes a
protein that contains several functional domains, including a tyrosine
kinase (TK)–binding domain, a RING finger (RF) domain, a con-
served Linker region between the TK-binding domain and RF in the
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N-terminal portion, and a C-terminal domain with ubiquitin ligase ac-
tivity [4]. The C-CBL protein has E3 ubiquitin ligase activity and is
responsible for the negative regulation of activated TKs [5,6]. The im-
portance of C-CBL gene in hematopoiesis has been demonstrated by
knockout mice that showed prolonged activation of TKs, enhanced
sensitivity to hematopoietic growth factors, expanded hematopoietic
stem cell pool, and myeloproliferative features [7–10].
Loss of heterozygosity could arise either by uniparental disomy
(UPD), which represent the coexistence of duplication of an entire
or partial chromosome from single parent and loss of the other allele,
or by hemizygous deletion. Application of single-nucleotide polymor-
phism (SNP)microarrays has facilitated the identifications of novel mu-
tated tumor suppressor genes or oncogenes with loss of normal alleles
[11,12]. Recently, the detection of 11q acquired UPD (aUPD) has led
to the identification of C-CBL mutations in various myeloproliferative
neoplasm or MDS subtypes [9,13–16], particularly in chronic myelo-
monocytic leukemia (CMML) with a frequency of 5% to 25%
[9,13,17–19]. We have further demonstrated that C-CBL mutations
result in a gain-of-function mutation if a tumor suppressor associated
with 11q aUPD, which is a novel leukemogenic mechanism in a subset
of CMML [9]. Of the previous studies, C-CBL mutations were mostly
analyzed on samples either at initial diagnosis or at the time of sAML
transformation. Two studies had examined paired MDS and sAML
samples; however, only one case each were included in their studies
[14,15]. The impact of C-CBLmutations on outcome of patients with
MDS and their role in the progression to sAML remain to be defined.
In this study, we analyzed a large cohort of matched paired bone mar-
row (BM) samples from 51 patients with de novo high-risk MDS and
its corresponding sAML to determine the frequency and characters of
C-CBLmutations at both phases of disease. The mutation status of the
C-CBL gene at either the diagnosis of MDS or sAML was correlated
with the clinicohematological features and outcome to determine its
clinical and prognostic relevance.
Design and Methods
Patients and Materials
Between 1991 and 2010, 167 patients with the diagnosis of high-
risk de novo MDS, including refractory cytopenia with multilineage
dysplasia (RCMD), refractory anemia with excess blast 1 (RAEB-1),
and refractory anemia with excess blast 2 (RAEB-2) were followed up
to observe the evolution of sAML. The morphologic subtypes of
MDS were classified according to the World Health Organization’s
classification [20]. Patients with CMML, refractory cytopenias with
unilineage dysplasia, refractory anemia with ring sideroblasts, MDS-
unclassified, MDS associated with isolated del(5q), and therapy-related
MDS were excluded. The cytogenetic findings according to the Interna-
tional Prognostic Scoring System (IPSS) were available in 138 patients
and were divided into three groups: 1) good = normal, −Y, del(5q),
del(20q); 2) poor = complex or chromosome 7 abnormalities; and 3)
intermediate = other abnormalities [21]. Eighty-six of 167 patients pro-
gressed to sAML, of which 51 patients (13 RCMD, 19 RAEB-1, and
19 RAEB-2) had matched paired BM samples at bothMDS and sAML
phases available for comparative analysis. They formed the basis of this
study. Forty-two patients (82.4%) in MDS phase received supportive
care only, five were treated with oral chemotherapy (hydroxyurea or
melphalan), one with low-dose cytarabine, and three with standard
AML protocol. Of the 51 patients at sAML phase, 15 were treated with
AML protocol, 2 proceeded to allogeneic hematopoietic stem cell trans-
plantation, 12 received low-dose cytarabine, 9 received oral chemo-
therapy, and 15 had supportive care only. The study was approved
by the institutional review boards of Chang Gung Memorial Hospital,
Taiwan, and the University of Tokyo, Japan.
Cell Fractionation
The mononuclear cells were obtained from BM samples by Ficoll-
Hypaque density gradient centrifugation (1.077 g/ml; Amersham
Pharmacia, Buckinghamshire, United Kingdom). The BM mono-
nuclear cells were cryopreserved in medium containing 10% dimethyl-
sulfoxide and 20% fetal bovine serum at −70°C or in liquid nitrogen
until test.
DNA, RNA Extraction, and Complementary
DNA Preparation
Genomic DNA (gDNA) and RNA were extracted from frozen BM
mononuclear cells. RNA was reversely transcribed to complementary
DNA (cDNA) with the SuperScript II RNase H2 Reverse Transcriptase
Kit (Invitrogen Corporation, Carlsbad, CA) as described previously [22].
C-CBL Mutation Analysis
cDNA polymerase chain reaction (PCR) assay was performed as
described previously [23]. For patients with available RNA samples,
the cDNA PCR products were either subjected to direct sequencing
and/or screened by denaturing high-performance liquid chromatog-
raphy (DHPLC; WAVE Transgenomic, Omaha, NE) system [24].
In the DHPLC assay system, we always ran a control of the patient’s
sample mixed with 50% wild-type DNA to distinguish homozygous
mutations from wild-type. The abnormal DHPLC profiles that sug-
gested the presence of mutations were then sequenced. For patients
without RNA samples available, mutations at exon 8 were all examined
by direct sequencing of gDNA PCR products, whereas mutations at
exons 7 and 9 were analyzed by either direct sequencing as previously
described [9] or with DHPLC system followed by sequencing for ab-
normal profiles obtained. The primer sequences for cDNA PCR and
DHPLC analysis are listed in Tables W1 and W2. All the mutations
detected were confirmed by using alternative samples and/or primers
and subjected to PCR assays with sequencing again.
Detection of Additional Gene Mutations
Mutational analysis of FLT3-ITD, FLT3-TKD, codons 12, 13, and
61 of N-RAS and K-RAS, C-KIT, and C-FMS (CSF1R) genes were per-
formed as described previously [3,25–27]. JAK2V617F and PTPN11
were analyzed according to the methods described by Baxter et al.
[28] and Tartaglia et al. [29], respectively.
SNP Microarray Analysis
High-density SNP array combined with CNAG (Copy Number
Analyzed for Affymetrix GeneChip Mapping)/AsCNAR (allele-specific
copy number analysis using anonymous references) software analysis
was performed using Affymetrix GeneChip 50K Xbal, HindIII, or
250K Nspl as described before [9], in four patients at sAML phase in
which C-CBL mutations were detected.
Statistical Analysis
Fisher exact test, χ2 analysis, and Wilcoxon rank sum test were used
whenever appropriate to make comparisons between groups. Estimates
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of survival were calculated according to the Kaplan-Meier method.
Comparisons of estimated survival curves were analyzed by the log-rank
test. Statistical analyses were carried out by software SPSS 17.0 (SPSS,
Inc, Chicago, IL). In all analyses, P values were two-sided and consid-
ered statistically significant when values lower than .05.
Results
C-CBL Mutations in Paired Samples of MDS and sAML
C-CBL mutation was detected in only 1 of 167 de novo high-risk
MDS at the initial diagnosis. Eighty-six patients progressed to sAML
with a median time of 9.8 months (range = 1.0-143.1 months). Of
the 51 paired MDS/sAML samples, 1 patient (no. 119) with RCMD
had a C-CBL mutation located at C-terminal of the RF domain
(G415S) at initial diagnosis; she retained the same C-CBL mutation
at sAML evolution. The other five patients acquired C-CBL muta-
tions during sAML transformation. Patient no. 109 with sAML trans-
formed from RCMD gained a missense mutation at the linker region
(L399V). Two sAML patients (nos. 001 and 125) transformed from
RAEB-1 gained a mutation at the linker region (Y371S) and the RF
domain (C416W), respectively. Of the two RAEB-2 patients who ac-
quired C-CBLmutations during sAML transformation, one (no. 010)
had a mutation at the RF domain (F418S) and the other (no. 032)
had an insertion mutation (L370_Y371 ins L) at the linker region.
The frequency of C-CBL mutations increased from 0.6% (1/167)
in the MDS phase to 11.8% (6/51) at sAML transformation. The
clinicohematological features and the C-CBL mutation status of the
six paired BM samples at both MDS and sAML phases are shown in
Table 1.
Figure 1 shows the sequencing electropherograms of the six paired
BM MDS/sAML samples carrying C-CBL mutations and the CNAG
output for the four sAML samples available for SNP array analysis.
Patient no. 001 acquired a homozygous mutation (Y371S) during
sAML evolution (Figure 1A). Patient no. 010 was negative for C-CBL
mutation at the initial diagnosis of MDS. She gained a small C-CBL
mutant clone in the follow-up sample 3.5 months later when her
disease was still in the MDS phase, and then she had an expansion
ofC-CBLmutant clone at the sAML phase 6 months after the diagnosis
of MDS. The SNP array analysis showed the presence of 11q-UPD at
the sAML phase; the UPD-positive cells were 33% calculated by the
observed difference in allele-specific copy number (ASCN) divided
by the expected value (Figure 1B), implying that the presence of a
homozygous mutation in a fraction of cells in patient no. 010. C-CBL
mutation was not detected in patient no. 032 at diagnosis of MDS but
a small mutant clone was identified at the sAML phase (Figure 1C ,
right upper panel). Because the allelic burden of the mutant clone was
very low, the PCR product was then cloned into the PCRII-TO PO
vector (Invitrogen). Twenty-six clones were subsequently sequenced
and six mutant clones were obtained, of which the sequence confirmed
the presence of L370_Y371L shown in Figure 1C , left lower panel.
The SNP array analysis revealed a small deletion and an amplification
at 11q23.3 in the sAML sample. Patient no. 109 acquired a missense
mutation (L399V) only after sAML transformation (Figure 1D). The
only one patient (no. 119) harboring the identical C-CBLmutations at
both MDS and sAML phases carried a small subclone of mutant at the
MDS phase and progressed to a higher level, which slightly exceeded
the wild-type allele. SNP array analysis for the sAML sample did not
reveal any abnormality in 11q23.3 (Figure 1E). Patient no. 125, neg-
ative for C-CBLmutation at MDS phase, acquired a missense mutation
(C416W) after sAML transformation (Figure 1F ). SNP array analysis
did not show an abnormal finding in 11q23.3 at the sAML phase.
Other Genetic Abnormalities in MDS/sAML Patients
Harboring C-CBL Mutations
Coexistence of additional gene mutations in C-CBL mutated pa-
tients was found in four of six patients (Table 2). Patient nos. 010,
119, and 125 acquired N-RAS mutation, JAK2V617F, and PTPN11
mutation, respectively, during sAML transformation. We did not find
any cooperating mutation involving receptor TKs (RTKs) or the RAS
pathway with C-CBL gene in patient nos. 001, 032, and 109. In ad-
dition, patient no. 125 had evidence of cytogenetic clonal evolution,
45,XX,−7[22/26]/46,XX[4/26] at MDS and 45,XX,−7[20/25]/45,
XX,−7,del(16)(q12.1)[2/25]/46,XX[3/25] at sAML.
Clinicohematological Features and Outcome of MDS/sAML
with C-CBL Mutations
Of the 51 patients, there was no difference in age, sex, hemoglobin
level, platelet counts, white blood cell counts, percentage of blasts in
BM or peripheral blood, cytogenetics, or IPSS (≤1.5 vs≥2.0) between
C-CBL mutation–positive and –negative groups at both MDS and
sAML. The time to sAML transformation and the survival from the
diagnosis of MDS in the six patients who harbored C-CBL mutations
at sAML phase are shown in Table 1. Because only one MDS patient
harbored C-CBL mutation at the initial diagnosis in the whole cohort
of MDS patients, it precluded a meaningful analysis of the mutation
status on the risk and time to sAML transformation or overall survival.
No significant difference in overall survival from the diagnosis of sAML
was observed regarding C-CBLmutation status (n = 51, estimated over-
all survival = 1.1 [95% confidence interval {CI} = 0-3.7] vs 5.6 [95%
Table 1. MDS/sAML Patients with C-CBL Mutations.
Patient No. Age (Year)/Sex WHO Subtype Marrow Blasts (%) Cytogenetics at MDS C-CBL Amino Acid Change IPSS Time to AML
(Months)
Survival from MDS
(Months)
MDS/sAML MDS sAML
001 70/F RAEB-1/sAML 5.5/71.7 NA — Y371S >1.0 3.5 3.9
010 48/F RAEB-2/sAML 17.0/32.2 46,XX,dup(1)(q21q32)[28/28] — F418S 2.5 5.3 28.1
032 72/M RAEB-2/sAML 16.6/79.0 46,XY,−5,−8,−9,add(11)(q25),
t(12;18)(p11;p11),−17,+4mar[6/20]
— L370_Y371 ins L 3.0 2.2 3.3
109 22/M RCMD/sAML 1.4/35.2 NA — L399V ≥0.5 7.0 7.6
119 54/F RCMD/sAML 5.0/59.0 NA G415S G415S 1.0 22.3 25.2
125 64/F RAEB-1/sAML 8.5/45.8 45,XX,−7[22/26]/46,XX[4/26] — C416W 1.5 14.9 23.8+
F indicates female; M, male; NA, not available; WHO, World Health Organization.
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Figure 1. Chromatograms of C-CBL mutations in six paired MDS/sAML samples (Wt, wild-type; Mu, mutant) and CNAG output for total
copy number (tCN) and allele-specific copy number (AsCNs) in the long arm of chromosome 11 in four patients at the sAML phase. The
green bars below each ideogram of 11q indicate the position of heterozygous SNP calls (red arrowhead). Dissociation of AsCN plot
indicates the presence of UPD in 11q. (A) Patient no. 001 acquired a homozygous missense mutation (Y371S) after sAML transforma-
tion. (B) Patient no. 010 had wild-type C-CBL gene at the initial diagnosis of RAEB-1, acquired a small missense mutant clone (C418S)
later, and the level of the mutant increased further at sAML phase. SNP array analysis at sAML revealed an 11q-UPD. (C) Patient no. 032,
negative for C-CBLmutation at the MDS phase, acquired L370_Y371 ins L at sAML phase. The small C-CBLmutant clone was confirmed
by TA cloning. SNP array analysis showed a small deletion and an amplification at 11q23.3 at the sAML phase. (D) Patient no. 109
acquired a missense mutation (L399V) only after sAML transformation. (E) Patient no. 119 had a small subclone of G415S mutant at
the MDS phase, which was more clearly shown in reverse complement and expanded during sAML transformation. SNP array analysis
for the sAML sample did not reveal any abnormality at 11q23.3. (F) Patient no. 125, negative for C-CBLmutation at MDS phase, acquired
a missense mutation (C416W) after sAML transformation. SNP array analysis did not show abnormal findings in 11q23.3 at sAML phase.
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CI = 2.9-8.3] months; P = .958; Figure 2) in patients with sAML
evolved from MDS.
Discussion
In the present study, an analysis of C-CBL mutations in the matched
paired BM samples from 51 patients at both phases of MDS and
sAML was performed. We found that only one MDS patient had
C-CBL mutation at initial presentation, and additional five patients
acquired C-CBL mutations during the disease progression to sAML.
The frequency of C-CBL mutations at MDS was very low and
markedly increased at sAML transformation (1/167 vs 6/51). To the best
of our knowledge, the present series is the first longitudinal and
Figure 1. (continued).
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systematical study that demonstrated the acquisition and/or clonal
expansion of C-CBL mutations in the progression of MDS to
sAML.
Because signaling of RTK-activating mutations, RAS pathways,
and C-CBL mutations are similar in cell models, we also performed
the mutational analyses for these genes. Coexistence of C-CBL muta-
tions with other gene mutations involving the RTKs and RAS path-
ways was common in our patients at the sAML phase. Three patients
had additional mutations of N-RAS, JAK2, or PTPN11 genes during
sAML evolution.The only oneMDS patient who retained the identical
C-CBL mutant clones at sAML transformation acquired JAK2V617F
during disease progression. These observations suggested that acquisi-
tion of C-CBL mutation collaborating with other gene mutations
played a role in the transformation of sAML from MDS. Furthermore,
a clonal cytogenetic evolution was also detected in one patient (no. 125)
during sAML progression. For those who did not harbor C-CBL mu-
tations at sAML phase, 10 patients acquired the activating mutations
in RTKs and/or RAS pathways (data not shown). Our result showed
that C-CBL mutations constituted one of the accumulated genetic
alternations associated with the progression of MDS to sAML.
Patient nos. 001, 032, and 109, who acquired C-CBL mutations at
sAML transformation, had only C-CBL mutations detected among
the genetic lesions we analyzed, suggesting that C-CBL mutations
might play a major role in the disease progression or cooperate with
other genetic abnormalities not examined in the present study for
these patients.
Patient no. 010 with wild-type C-CBL gene at initial diagnosis of
MDS acquired C-CBL mutation later when her disease was still in the
MDS phase and the mutant level increased further in the sAML phase.
The presence of UPD-positive cells in a subfraction of cells (33%) cal-
culated by a signal ratio attributed to the presence of 11qUPD at the
sAML phase in this case without accompanying a homozygous se-
quencing electropherogram. In patient no. 119 carrying C-CBL muta-
tions in both MDS and sAML phases, the very small C-CBL mutant
clone expanded to a slightly predominant clone during sAML evolution
in the absence of UPD in the CNAG output. The observed discrepancy
might be explained as an allele measurement on sequencing electrophe-
rogram probably not accurately enough to conclude the predominance
of the mutant allele based on such a subtype difference of signals.
Barresi et al. [14] also described an expansion of C-CBL mutated sub-
clone occurred in a case during MDS progression to sAML. This find-
ing indicated that the C-CBL mutated subclone conferred a growth
advantage whenMDS progressed to sAML. Acquisition with expansion
of C-CBL mutated clones was also reported in one patient during the
progression of primary myelofibrosis to sAML [30].
The sequencing analysis showed that five of the six C-CBL muta-
tions in MDS or sAML were missense mutations; the remaining one
was an insertion mutation. All of the C-CBL mutations found in our
patients involved the linker region or RF domain that is central to the
E3 ubiquitin ligase activity [5,6]. Because we analyzed mutations spe-
cifically at exons 7, 8, and 9, C-CBLmutations located outside exons 7
to 9 would not be detected in the present study. It is of note that most
of the C-CBL mutations reported previously was missense mutation.
Insertion mutations were only described in one AML patient with
ins(SK366) at intron7/exon8 splice site [31]. The mutation character
of three-base insertion that leads to L370_Y371 ins L without frameshift
at the linker region of C-CBL, which was verified by cloning analysis,
had not been described before. L370_Y371 ins L might cause conforma-
tional change of the Linker region and result in decreased E3 activity. It
has been found that homozygous C-CBL mutations were frequently ob-
served in patients with CMML and strongly associated with 11q aUPD
[9,13,19]. In the present study, we found that UPD seemed to be less
frequent in patients with MDS/sAML.
Table 2. Additional Gene Mutations in MDS/sAML Patients Harboring C-CBL Mutations.
Patient No. Mutation Status at MDS/sAML Phase
C-CBL Amino Acid Change N-RAS K-RAS FLT3-ITD FLT3-TKD (D835) JAK2V617F PTPN11 C-KIT C-FMS
001 −/+ (Y371S) −/− −/− −/− −/− −/− −/− −/− −/−
010 −/+/+ (F418S)* −/+ (Q61H) −/− −/− −/− −/− −/− −/− −/−
032 −/+ (L370_Y371 ins L) −/− −/− −/− −/− −/− −/− −/− −/−
109 −/+ (L399V) −/− −/− −/− −/− −/− −/− −/− −/−
119 +/+ (G415S) −/− −/− −/− −/− −/++ ND/− −/− ND/−
125 −/+ (C416W) −/− −/− −/− −/− −/− −/+ (Q510L) −/− ND/ND
++ indicates homozygous mutation; ND, not done.
*Mutation status at MDS/MDS/sAML phases.
Figure 2. Kaplan-Meier estimates of overall survival in sAML pa-
tients according to C-CBL mutation status. The survival from the
diagnosis of sAML was 1.1 months (95% CI = 0-3.7) for the patient
with C-CBLmutation compared with the estimated median survival
of 5.6 months (95% CI = 2.9-8.3) in C-CBL mutation–negative
patients (P = .958).
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Whether C-CBL mutations confer unique clinical characteristics is
not clearly defined. We did not find any association between C-CBL
mutations and specific clinicohematological features at the initial pre-
sentation or at sAML. In the literature review along with the present
result, except for one with refractory anemia [19], MDS patients har-
boring C-CBL mutations were mostly of RAEB or RCMD subtypes
[9,13–15]. Current evidences suggested that C-CBL mutations were
associated with more aggressive types of MDS. The impact of C-CBL
mutations on clinical outcome in MDS is not known because of the
rare occurrence of the mutation at the initial diagnosis. The clinical
and prognostic relevance of C-CBL mutation on MDS remains to be
determined by a larger cohort of patients. We did not observe a survival
impact of C-CBL mutation in sAML patients. Our patients received
different treatment options both at MDS and sAML stages; this might
have influences on survival analysis. Nevertheless, sAML has a very
poor prognosis; the cohort of patients that carrying C-CBL mutations
in this series would have a poor outcome. It is the fact that C-CBL
mutation in sAML evolution is of biologic relevance but not necessary
of prognostic importance.
To sum up, we analyzed C-CBL mutations in matched paired BM
samples of patients with high-risk de novoMDS at initial presentation
and sAML. Our results showed that C-CBL mutations were rare in
MDS at the presentation, but acquisition and/or expansion of C-CBL
mutated clones occurred not infrequently during its progression to
sAML. The higher occurrence of C-CBL mutations at sAML transfor-
mation in patients with MDS suggested that C-CBL mutation might
play a role, either dominantly or cooperatively with other genetic abnor-
malities, in a subset of MDS patients during sAML evolution.
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Table W1. Primers for C-CBL Mutation Analysis by cDNA PCR Assay.
Primer Name Primer Sequence 5′→3′ Amplicon Size (bp) Method
CBL-ex6-F CTCCAGACAATCCCTCACAATAAA 350 DHPLC
CBL-ex9-R ACCACGATGGGTTCAGTACCTTTA
CBL-ex8-9-F ACTGTGAGATGGGCTCCACATT 374 DHPLC
CBL-ex8-9-R-gc cggcgggggcGAAGCTTGTGGGGCCATG
CBL-ex6-F CTCCAGACAATCCCTCACAATAAA 533 Direct sequencing
CBL-ex8-9-R GAAGCTTGTGGGGCCATG
Table W2. Primers for C-CBL Mutation Analysis by gDNA PCR Assay.
Primer Name Primer Sequence 5′→3′ Amplicon Size (bp) Method
CBL-ex7-F-gc cgcccgccgccgcccGGCAAATTGGCTTAAATAAAACC 187 DHPLC
CBL-ex7-R GTGTCCAGTGATATGGTTATCATG
CBL-ex9-F CTATCTTTTGCTTCTTCTGCA 323 DHPLC
CBL-ex9-R-gc gacgggcggcgggcggcggcgggcgTCGTTAAGTGTTTTACGGCTTTAG
CBL-7F CTTACACCACGTTGCCCTTT 364 Direct sequencing
CBL-7R TGGGTCCTATTTTAAGCTCCA
CBL-8F AGGACCCAGACTAGATGCTTTC 387 Direct sequencing
CBL-8R GGCCACCCCTTGTATCAGTA
CBL-9F CTGGCTTTTGGGGTTAGGTT 400 Direct sequencing
CBL-9R TCGTTAAGTGTTTTACGGCTTT
